J2351 Injection, ocrelizumab, 1 mg and hyaluronidase-ocsq
Billable / valid for submission HCPCS Release 2026Q3
Short description: Inj ocrelizumab 1mg hya-ocsq
Version history
| Release | Valid from | Valid to | Description | Billable |
|---|---|---|---|---|
| 2026Q3 | 2026-07-01 | current | Injection, ocrelizumab, 1 mg and hyaluronidase-ocsq | yes |
Related codes in J23
- J2300 Injection, nalbuphine hydrochloride, per 10 mg
- J2305 Injection, nitroglycerin, 5 mg
- J2312 Injection, naloxone hydrochloride, not otherwise specified, 0.01 mg
- J2313 Injection, naloxone hydrochloride (zimhi), 0.01 mg
- J2315 Injection, naltrexone, depot form, 1 mg
- J2320 Injection, nandrolone decanoate, up to 50 mg
- J2323 Injection, natalizumab, 1 mg
- J2325 Injection, nesiritide, 0.1 mg
- J2326 Injection, nusinersen, 0.1 mg
- J2327 Injection, risankizumab-rzaa, intravenous, 1 mg
- J2329 Injection, ublituximab-xiiy, 1mg
- J2350 Injection, ocrelizumab, 1 mg
- J2353 Injection, octreotide, depot form for intramuscular injection, 1 mg
- J2354 Injection, octreotide, non-depot form for subcutaneous or intravenous injection, 25 mcg
- J2355 Injection, oprelvekin, 5 mg
- J2356 Injection, tezepelumab-ekko, 1 mg
- J2357 Injection, omalizumab, 5 mg
- J2358 Injection, olanzapine, long-acting, 1 mg
- J2359 Injection, olanzapine, 0.5 mg
- J2360 Injection, orphenadrine citrate, up to 60 mg